Systemic Profiling of KDM5 Subfamily Signature in Non-Small-Cell Lung Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-based lung cancer screening: a systematic review. Lung Cancer. 2020;147:154–186. doi:10.1016/j.lungcan.2020.07.007
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–1242. doi:10.1097/JTO.0000000000000663
   PubMed Web of Science ®Google Scholar
• Takamochi K, Ohmiya H, Itoh M, et al. Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung. BMC Cancer. 2016;16(1):760. doi:10.1186/s12885-016-2792-1
   PubMed Web of Science ®Google Scholar
• Højfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12(12):917–930. doi:10.1038/nrd4154
   PubMed Web of Science ®Google Scholar
• Arifuzzaman S, Khatun MR, Khatun R. Emerging of lysine demethylases (KDMs): from pathophysiological insights to novel therapeutic opportunities. Biomed Pharmacother. 2020;129:110392.
   PubMed Web of Science ®Google Scholar
• Blair LP, Cao J, Zou MR, Sayegh J, Yan Q. Epigenetic regulation by lysine demethylase 5 (KDM5) enzymes in cancer. Cancers. 2011;3(1):1383–1404. doi:10.3390/cancers3011383
   PubMedGoogle Scholar
• Dorosz J, Kristensen LH, Aduri NG, et al. Molecular architecture of the Jumonji C family histone demethylase KDM5B. Sci Rep. 2019;9(1):4019. doi:10.1038/s41598-019-40573-y
   PubMed Web of Science ®Google Scholar
• Pilka ES, James T, Lisztwan JH. Structural definitions of Jumonji family demethylase selectivity. Drug Discov Today. 2015;20(6):743–749. doi:10.1016/j.drudis.2014.12.013
   PubMed Web of Science ®Google Scholar
• Rondinelli B, Schwerer H, Antonini E, et al. H3K4me3 demethylation by the histone demethylase KDM5C/JARID1C promotes DNA replication origin firing. Nucleic Acids Res. 2015;43(5):2560–2574. doi:10.1093/nar/gkv090
   PubMed Web of Science ®Google Scholar
• Li N, Dhar SS, Chen TY, et al. JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Res. 2016;76(4):831–843. doi:10.1158/0008-5472.CAN-15-0906
   PubMed Web of Science ®Google Scholar
• Plch J, Hrabeta J, Eckschlager T. KDM5 demethylases and their role in cancer cell chemoresistance. Int J Cancer. 2019;144(2):221–231. doi:10.1002/ijc.31881
   PubMed Web of Science ®Google Scholar
• Hinohara K, Wu HJ, Vigneau S, et al. KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell. 2018;34(6):939–953.e9. doi:10.1016/j.ccell.2018.10.014
   PubMed Web of Science ®Google Scholar
• Oser MG, Sabet AH, Gao W, et al. The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 2019;33(23–24):1718–1738. doi:10.1101/gad.328336.119
   PubMed Web of Science ®Google Scholar
• Bamodu OA, Huang W-C, Lee W-H, et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer. 2016;16(1):160. doi:10.1186/s12885-016-2108-5
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–49.
   PubMed Web of Science ®Google Scholar
• Komura K, Jeong SH, Hinohara K, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci. 2016;113(22):6259–6264. doi:10.1073/pnas.1600420113
   PubMed Web of Science ®Google Scholar
• Kaewkangsadan V, Verma C, Eremin MJ, Cowley G, Ilyas M, Eremin O. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC. BMC Cancer. 2018;18:123.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812–830.
   PubMed Web of Science ®Google Scholar
• Gong F, Miller KM. Histone methylation and the DNA damage response. Mutat Res. 2019;780:37–47. doi:10.1016/j.mrrev.2017.09.003
   Web of Science ®Google Scholar
• Lee DH, Kim GW, Jeon YH, Yoo J, Lee SW, Kwon SH. Advances in histone demethylase KDM4 as cancer therapeutic targets. FASEB J. 2020;34(3):3461–3484. doi:10.1096/fj.201902584R
   PubMed Web of Science ®Google Scholar
• Chi P, Allis CD, Wang GG. Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10(7):457–469. doi:10.1038/nrc2876
   PubMed Web of Science ®Google Scholar
• Chicas A, Kapoor A, Wang X, et al. H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci USA. 2012;109(23):8971–8976. doi:10.1073/pnas.1119836109
   PubMed Web of Science ®Google Scholar
• Defeo-Jones D, Huang PS, Jones RE, et al. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature. 1991;352(6332):251–254. doi:10.1038/352251a0
   PubMed Web of Science ®Google Scholar
• Hou J, Wu J, Dombkowski A, et al. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 2012;4(3):247–256.
   PubMed Web of Science ®Google Scholar
• Romani M, Daga A, Forlani A, Pistillo MP, Banelli B. Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of temozolomide-resistant glioblastoma cells. Cancers. 2019;11(6):878. doi:10.3390/cancers11060878
   PubMed Web of Science ®Google Scholar
• Zeng J, Ge Z, Wang L, et al. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology. 2010;138(3):981–992. doi:10.1053/j.gastro.2009.10.004
   PubMed Web of Science ®Google Scholar
• Liang X, Zeng J, Wang L, et al. Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS One. 2013;8(7):e69784. doi:10.1371/journal.pone.0069784
   PubMed Web of Science ®Google Scholar
• Teng YC, Lee CF, Li YS, et al. Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res. 2013;73(15):4711–4721. doi:10.1158/0008-5472.CAN-12-3165
   PubMed Web of Science ®Google Scholar
• Lu PJ, Sundquist K, Baeckstrom D, et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem. 1999;274(22):15633–15645. doi:10.1074/jbc.274.22.15633
   PubMed Web of Science ®Google Scholar
• Roesch A, Vultur A, Bogeski I, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013;23(6):811–825. doi:10.1016/j.ccr.2013.05.003
   PubMed Web of Science ®Google Scholar
• Niu X, Zhang T, Liao L, et al. The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene. 2012;31(6):776–786. doi:10.1038/onc.2011.266
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xu L, Wang J, et al. KDM5C expedites lung cancer growth and metastasis through epigenetic regulation of microRNA-133a. Onco Targets Ther. 2021;14:1187–1204. doi:10.2147/OTT.S288799
   PubMed Web of Science ®Google Scholar
• Akimoto C, Kitagawa H, Matsumoto T, Kato S. Spermatogenesis-specific association of SMCY and MSH5. Genes Cells. 2008;13(6):623–633. doi:10.1111/j.1365-2443.2008.01193.x
   PubMed Web of Science ®Google Scholar
• Willis-Owen SAG, Domingo-Sabugo C, Starren E, et al. Y disruption, autosomal hypomethylation and poor male lung cancer survival. Sci Rep. 2021;11(1):1245. doi:10.1038/s41598-021-91907-8
   PubMed Web of Science ®Google Scholar
• Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights into lung cancer immune-based biology, prevention, and treatment. Front Immunol. 2020;11:159. doi:10.3389/fimmu.2020.00159
   PubMed Web of Science ®Google Scholar
• Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125(9):3347–3355. doi:10.1172/JCI80007
   PubMed Web of Science ®Google Scholar
• Lee N, Zakka LR, Mihm MC Jr, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48(2):177–187. doi:10.1016/j.pathol.2015.12.006
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28(1):445–489. doi:10.1146/annurev-immunol-030409-101212
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91–98. doi:10.1158/2326-6066.CIR-13-0216
   PubMed Web of Science ®Google Scholar
• Chang SH. T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res. 2019;42(7):549–559. doi:10.1007/s12272-019-01146-9
   PubMed Web of Science ®Google Scholar
• Moreno Ayala MA, Li Z, DuPage M. Treg programming and therapeutic reprogramming in cancer. Immunology. 2019;157(3):198–209. doi:10.1111/imm.13058
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Targeting treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140–1146. doi:10.1002/eji.201847659
   PubMed Web of Science ®Google Scholar
• Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302–316. doi:10.1016/j.immuni.2019.01.020
   PubMed Web of Science ®Google Scholar
• Duan MC, Han W, Jin PW, et al. Disturbed Th17/Treg balance in patients with non-small cell lung cancer. Inflammation. 2015;38(6):2156–2165. doi:10.1007/s10753-015-0198-x
   PubMed Web of Science ®Google Scholar
• Salazar Y, Zheng X, Brunn D, et al. Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. J Clin Invest. 2020;130(7):3560–3575. doi:10.1172/JCI124037
   PubMed Web of Science ®Google Scholar
• Geis AL, Fan H, Wu X, et al. Regulatory T-cell response to enterotoxigenic bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov. 2015;5(10):1098–1109. doi:10.1158/2159-8290.CD-15-0447
   PubMed Web of Science ®Google Scholar